Veracyte Historical Balance Sheet
VCYT Stock | USD 42.95 0.06 0.14% |
Trend analysis of Veracyte balance sheet accounts such as Total Assets of 1.2 B, Other Current Liab of 37.9 M, Total Current Liabilities of 64.3 M or Total Stockholder Equity of 1.1 B provides information on Veracyte's total assets, liabilities, and equity, which is the actual value of Veracyte to its prevalent stockholders. By breaking down trends over time using Veracyte balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Veracyte latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Veracyte is a good buy for the upcoming year.
Veracyte Inventory |
|
Veracyte |
About Veracyte Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Veracyte at a specified time, usually calculated after every quarter, six months, or one year. Veracyte Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Veracyte and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Veracyte currently owns. An asset can also be divided into two categories, current and non-current.
Veracyte Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Veracyte assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Veracyte books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Veracyte balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Veracyte are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Most accounts from Veracyte's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Veracyte current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.At this time, Veracyte's Net Receivables is comparatively stable compared to the past year. Common Stock Total Equity is likely to gain to about 86.9 K in 2024, despite the fact that Retained Earnings are likely to grow to (444.7 M).
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 38.8M | 40.0M | 36.1M | 37.9M | Total Assets | 1.2B | 1.2B | 1.1B | 1.2B |
Veracyte balance sheet Correlations
Click cells to compare fundamentals
Veracyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Veracyte balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 275.2M | 457.2M | 1.2B | 1.2B | 1.1B | 1.2B | |
Other Current Liab | 13.7M | 10.1M | 38.8M | 40.0M | 36.1M | 37.9M | |
Total Current Liabilities | 17.5M | 16.8M | 64.2M | 62.6M | 61.2M | 64.3M | |
Total Stockholder Equity | 239.5M | 421.2M | 1.1B | 1.1B | 1.0B | 1.1B | |
Other Liab | 6.1M | 8.4M | 13.1M | 7.6M | 8.7M | 5.6M | |
Property Plant And Equipment Net | 17.7M | 16.8M | 31.1M | 30.9M | 30.9M | 32.4M | |
Net Debt | (145.7M) | (337.0M) | (154.3M) | (139.5M) | (203.8M) | (193.6M) | |
Retained Earnings | (246.7M) | (281.6M) | (357.2M) | (393.7M) | (468.1M) | (444.7M) | |
Accounts Payable | 2.3M | 3.1M | 12.4M | 11.9M | 12.9M | 13.6M | |
Cash | 159.3M | 349.4M | 173.2M | 154.2M | 216.5M | 117.7M | |
Non Current Assets Total | 87.5M | 81.5M | 944.7M | 907.8M | 829.3M | 870.7M | |
Non Currrent Assets Other | 2.0M | 2.0M | (35.1M) | (26.8M) | 6.8M | 7.2M | |
Other Assets | 2.0M | 9.8M | 2.9M | 6.2M | 1.0 | 0.95 | |
Cash And Short Term Investments | 159.3M | 349.4M | 173.2M | 178.9M | 216.5M | 119.7M | |
Net Receivables | 19.3M | 18.5M | 41.5M | 44.0M | 40.4M | 42.4M | |
Common Stock Total Equity | 50K | 58K | 71K | 72K | 82.8K | 86.9K | |
Common Stock Shares Outstanding | 46.1M | 53.2M | 67.9M | 71.5M | 72.6M | 41.6M | |
Liabilities And Stockholders Equity | 275.2M | 457.2M | 1.2B | 1.2B | 1.1B | 1.2B | |
Non Current Liabilities Total | 18.3M | 19.2M | 27.2M | 18.6M | 9.6M | 17.6M | |
Inventory | 6.8M | 4.7M | 11.2M | 14.3M | 16.1M | 16.9M | |
Other Current Assets | 2.2M | 3.2M | 17.2M | 11.5M | 12.7M | 13.3M | |
Other Stockholder Equity | 486.1M | 702.8M | 1.5B | 1.5B | 1.5B | 1.6B | |
Total Liab | 35.8M | 35.9M | 91.3M | 81.2M | 70.8M | 44.5M | |
Property Plant And Equipment Gross | 17.7M | 9.0M | 31.1M | 30.9M | 63.7M | 66.9M | |
Total Current Assets | 187.7M | 375.7M | 243.1M | 248.6M | 285.6M | 148.7M | |
Accumulated Other Comprehensive Income | (12.0M) | 0.0 | (15.1M) | (31.3M) | (24.0M) | (22.8M) | |
Common Stock | 50K | 58K | 71K | 72K | 73K | 42.9K | |
Property Plant Equipment | 8.9M | 9.0M | 31.1M | 30.9M | 35.5M | 37.3M | |
Short Long Term Debt Total | 13.6M | 12.3M | 18.9M | 14.7M | 12.6M | 16.8M | |
Net Tangible Assets | 171.7M | 358.6M | 185.9M | 379.3M | 436.2M | 458.0M | |
Long Term Debt | 25.2M | 23.9M | 694K | 810K | 931.5K | 884.9K | |
Retained Earnings Total Equity | (246.7M) | (281.6M) | (357.2M) | (393.7M) | (354.3M) | (372.1M) | |
Long Term Debt Total | 25.2M | 23.9M | 694K | 810K | 931.5K | 884.9K | |
Capital Surpluse | 486.1M | 702.8M | 1.5B | 1.5B | 1.7B | 1.8B | |
Deferred Long Term Liab | 4.2M | 3.9M | 5.6M | 4.5M | 5.2M | 4.3M | |
Intangible Assets | 65.0M | 59.9M | 202.7M | 174.9M | 88.6M | 66.2M | |
Short Term Debt | 1.4M | 3.2M | 8.4M | 8.1M | 10.2M | 7.5M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.